TABLE 2.
Tabulated results of the metabolite and hormone analysis
| Lean (n = 10) | Overweight (n = 13) | p values | |||||
|---|---|---|---|---|---|---|---|
| IN‐PLA | IN‐INS | IN‐PLA | IN‐INS | Treatment | Group | Treatment × group interaction | |
| plasma glucose (mmol/l) | −0.05 (0.28) | −0.2 (0.2) | 0 (0.1) | −0.1 (0.4) | .031* | .63 | .48 |
| serum insulin (mIU/l) | −0.15 (1.18) | −0.75 (13.68) | −1.4 (2,9) | 2.0 (8.8) | .41 | .33 | .61 |
| serum C‐peptide (pmol/l) | −46.5 (64.75) a | −103.5 (96.75) a | −69.0 (68) | −111 (198) | .015* | .70 | .880 |
Note: Analysis was conducted on (post–pre) levels. A significant treatment effect was seen for serum C‐peptide. Lean (n = 10), OW (n = 13). * p < .05. Data are presented as median (IQR).
a
Significant post hoc test, that describes IN‐INS associated C‐peptide suppression over time as greater than IN‐PLA for the lean group only.